Stock Events

Stock Events

Eledon Pharmaceuticals 

$3.08
0
+$0.2+6.94% Wednesday 05:49

Statistics

Day High
3.08
Day Low
2.88
52W High
-
52W Low
-
Volume
282
Avg. Volume
-
Mkt Cap
184.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.25
-0.2
-0.16
-0.11
Expected EPS
-0.182
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-80.22MNet Income

Analyst Ratings

$8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ELDN.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurodegenerative diseases, directly competing with Eledon's focus on neurological conditions.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO is involved in gene therapy for neurodegenerative diseases, overlapping with Eledon's therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, competing in the same space as Eledon's focus on treatments for autoimmune diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics for genetic diseases, some of which are in direct competition with Eledon's focus areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals engages in creating treatments for serious diseases, including cystic fibrosis, which could overlap with Eledon's target disease areas.
Novartis
NVS
Mkt Cap237.61B
Novartis offers a broad range of healthcare solutions, including treatments for neurological conditions that compete with Eledon's portfolio.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for neurological and autoimmune diseases, competing with Eledon's research areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, known for antiviral drugs, also explores treatments in areas that could compete with Eledon's focus on autoimmune diseases.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a diverse portfolio, including drugs for neurological and autoimmune disorders, directly competing with Eledon Pharmaceuticals.

About

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Show more...
CEO
ISIN
US28617K1016

Listings

BOATS
BOATS
ELDN.BOATS
F
DE
2TK.F
XNAS
US
ELDN

0 Comments

Share your thoughts

FAQ

What is Eledon Pharmaceuticals stock price today?▼
The current price of ELDN.BOATS is $3.08 USD — it has increased by +6.94% in the past 24 hours. Watch Eledon Pharmaceuticals stock price performance more closely on the chart.
What is Eledon Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Eledon Pharmaceuticals stocks are traded under the ticker ELDN.BOATS.
What is Eledon Pharmaceuticals market cap?▼
Today Eledon Pharmaceuticals has the market capitalization of 184.44M
When is the next Eledon Pharmaceuticals earnings date?▼
Eledon Pharmaceuticals is going to release the next earnings report on May 07, 2026.
What were Eledon Pharmaceuticals earnings last quarter?▼
ELDN.BOATS earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.2 USD resulting in a +45.9% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Eledon Pharmaceuticals revenue for the last year?▼
Eledon Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Eledon Pharmaceuticals net income for the last year?▼
ELDN.BOATS net income for the last year is -80.22M USD.
When did Eledon Pharmaceuticals complete a stock split?▼
Eledon Pharmaceuticals has not had any recent stock splits.